Medical/Pharmaceuticals

Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific Advisor for its CoviDTH program,Yvelise Barrios, MD, PhD, and Clinical Immuno...

2021-09-07 20:00 6835

Medwish.com Launches Global Free Shipping Plan to Deliver Medical Equipment to Hospitals

SHANGHAI, Sept. 7, 2021 /PRNewswire/ -- Medwish.com, the online B2B medical equipment marketplace, today announced it will offer free shipping on more than 10,000 medical products in its full 14 sub-categories covering hospital beds, patient monitors, compressor nebulizers, oxygen concentrators, ...

2021-09-07 19:26 3033

Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2021-09-07 19:04 5585

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...

2021-09-07 19:00 3358

Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation

HONG KONG, Sept. 7, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI) -driven drug discovery company, specialized in target discovery, small molecule chemistry, and clinical development, announced a collaboration with theUniversity of Cambridge. The agreement out...

2021-09-07 18:15 3332

Ethics Approval Granted for Clinical Trial of World's First Nasal Swab Designed Specifically for Children

* Rhinomed has created the world's first nasal swab designed specifically for children — The Rhinoswab Junior™ * Ethics approval has been received for a clinical trial to commence with the Murdoch Children's Research Institute (MCRI) at The Royal Children's Hospital in Melbourne * Trial seek...

2021-09-07 18:00 2753

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

- Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placeb...

2021-09-07 18:00 4227

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited announced the appointment ofGiuliano Perfetti as its Chief Executive Officer. Mr. Giuliano Perfetti joins as CEO Jubilant Bio...

2021-09-07 16:11 5659

MIM Software Inc. Announces AI Segmentation and Single Timepoint Dosimetry Capabilities for Molecular Radiotherapy

CLEVELAND, Sept. 7, 2021 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imaging software, announced today new innovations to MIM SurePlan™ MRT, its software package for Molecular Radiotherapy. MIM SurePlan MRT has received CE Mark approval for new artificial intelligence...

2021-09-07 15:00 3663

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

-- Using NeuExcell's neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington's Disease. -- Spark Therapeutics' excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform ma...

2021-09-07 12:00 4149

Major new study reveals that half of all people fear the internet and smartphones are damaging wellbeing

DHAHRAN, Saudi Arabia, Sept. 7, 2021 /PRNewswire/ -- As the world adjusts to a post-pandemic reality dominated by technology, public concerns about the dangers of over-consumption are gathering pace. According to a major new survey[1] from Saudi-based cultural institute,Ithra

2021-09-07 08:01 5418

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

* The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally * Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, g...

2021-09-06 19:03 5673

GenScript ProBio Enters into Agreement with SYNIMMUNE for Manufacturing of their Innovative Antibody Drug

NANJING, China, Sept. 6, 2021 /PRNewswire/ -- GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production. FLYSYN is a fms-like tyrosine kinase 3 (FLT3) specific antibody for the ...

2021-09-06 16:00 3436

Inspiration Capital Partners announces Investment in Beijing Loving Care International Pet Medical Center

SHANGHAI, Sept. 6, 2021 /PRNewswire/ -- Inspiration Capital Partners ("ICP") today announced an investment in Beijing Loving Care International Pet Medical Center ("Loving Care"). Founded in 2013, Loving Care is a leading premium specialty pet healthcare chain, focusing on providing high quality...

2021-09-06 15:32 3777

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...

2021-09-06 13:44 4385

Kintor Pharma Included in Hong Kong Stock Connect Program

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hong Kong Stock Conn...

2021-09-06 11:30 4529

CStone Pharmaceuticals Included in the Hong Kong Stock Connect

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, announced that the Company has been...

2021-09-06 11:30 4697

Lunit AI Receives HSA Approval, Now Commercially Available in Singapore

* Lunit AI products for analyzing chest X-ray and mammograms now approved to support medical professionals ofSingapore, by detecting suspicious lesions with 96-99% accuracy * Applied in one of Singapore's leading healthcare center, with positive feedback from the users SEOUL, South Korea, Sep...

2021-09-06 09:30 2447

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

SUZHOU, China, Sept. 5, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1...

2021-09-06 09:00 1851

Gannex Announces Clinical Trial Application of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis Accepted by China NMPA

SHANGHAI, Sept. 6, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the clinical trial application of ASC42 to treat patients with primary biliary cholangitis (PBC) has been accepted for review by China National Medical ...

2021-09-06 08:30 3845
1 ... 589590591592593594595 ... 646